Objetivo del tratamiento del cáncer renal: supervivencia y calidad de vida de los pacientes

Treatment-naïve

mRCC with a clear-

cell component

N = 1070

Nivolumab 3 mg/kg plus

Ipilimumab 1 mg/kg IV

every 3 weeks x 4 doses

then Nivolumab 3 mg/kg

every 2 weeks

Sunitinib

50 mg orally

once daily

4w on/2w off

Randomize

1:1

Co-primary endpoints: ORR, PFS and OS in intermediate- and poor-risk patients

NCT02231749

Stratified by:

• IMDC risk (G/I/P)

• Region